Skip to content

ICAAC: Gains in limb fat and CD4 counts continue three years after switching from d4T to tenofovir

Return of nelfinavir's European license recommended

ICAAC: Maraviroc failures associated with shifts from R5-tropic to mixed or X4-tropic HIV

ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance

ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents

Virologically failing NNRTI regimens have higher resistance risk than failing boosted-PIs

Switch to nevirapine safe for treatment-experienced patients with high CD4 cell counts

Apricitabine strong in phase 2 study, 24-week data released

IAS: Maraviroc produces best results when combined with another active drug